Lagroben (Carmellose Sodium)

Carmellose sodium is a cellulose derivative that increases the viscosity of the tear film. By thickening the tear layer, it prolongs tear residence time on the eye, improves lubrication, and creates a protective barrier that shields the cornea and conjunctiva from friction and environmental stress.

The dosing regimen for Lagroben is determined by the prescribing clinician based on the patient’s condition. Typically, one to two drops are instilled in the affected eye(s) as needed, but the exact frequency and duration should follow the healthcare professional’s instructions.

Safety data for carmellose sodium in pregnancy and lactation are limited. It should be used only if clearly needed and after a risk‑benefit assessment by the prescriber. Women who are pregnant or breastfeeding should discuss potential risks with their healthcare provider.

To order Lagroben, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Lagroben’s active ingredient, carmellose sodium, provides high viscosity and long‑lasting lubrication, similar to hyaluronic acid‑based drops. Compared with simple saline solutions, Lagroben offers better tear‑film stability and longer symptom relief, making it a preferred option for moderate to severe dry eye and intra‑operative lubrication.

Lagroben should be stored at room temperature, below 25 °C, in its original container. Protect the bottle from direct sunlight, moisture and extreme temperatures. Keep the cap tightly closed when not in use to maintain sterility.

Lagroben is applied topically to the eye. The patient should wash their hands, tilt the head back, pull down the lower eyelid, and place one drop into the conjunctival sac. The eye can be closed gently for a few seconds to aid distribution.

Although rare, serious adverse events include severe allergic reactions such as anaphylaxis, corneal ulceration, persistent eye pain, sudden loss of vision, and intra‑ocular inflammation. Any of these symptoms require immediate medical attention.

Lagroben should be avoided in individuals with a known hypersensitivity to carmellose sodium or any excipients in the formulation. It is also contraindicated in eyes with active infection or severe inflammation until the underlying condition is treated.